How does PT-141 work?
PT-141, or bremelanotide, switches on melanocortin receptors. It acts in the brain, on melanocortin pathways tied to desire, mainly MC4R. It does not work on blood flow to the genitals the way erection drugs (PDE5 inhibitors) do. This site's profile says the body clears half of it in about 2.7 hours. Its molecular weight is 1,025.2 daltons. Its June 2019 approval as Vyleesi covers low sexual desire that causes distress in women who have not reached menopause. That is based on RECONNECT, in 1,267 women over 24 weeks. Desire scores rose by 0.35 on a desire questionnaire (the FSFI desire scale) compared with a dummy shot. Nausea, flushing, and headache each showed up in 10% or more. The label warns that blood pressure goes up for a short time after each dose. Use in men is off-label. A research-chemical vial is not that labeled pen. This FAQ does not invent a dose. Full record at /compounds/pt-141.
Studies in people from the compound pages this answer belongs to
- PT-141
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT) 2019 PMID 31599840
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder 2019 PMID 31599847
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide 2017 PMID 27977473
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of sexual health and hormone peptides. PT-141, melanotan, oxytocin, gonadorelin, and kisspeptin-10.